LC-MSn analysis of metabolites of 1,2-bis (1,2-benzisoselenazolone-3(2H)-ketone)-ethane, a novel anti-cancer agent in rat.
- Author:
Hai-Yan ZHOU
1
;
Zhi-Yun MENG
;
Gui-Fang DOU
;
Jin-Lan MA
;
Ya-Qing LOU
;
Guo-Liang ZHANG
Author Information
1. Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China.
- Publication Type:Journal Article
- MeSH:
Administration, Oral;
Animals;
Antineoplastic Agents;
administration & dosage;
blood;
metabolism;
urine;
Bile;
metabolism;
Bridged Bicyclo Compounds, Heterocyclic;
administration & dosage;
blood;
metabolism;
urine;
Chromatography, Liquid;
Feces;
chemistry;
Male;
Organoselenium Compounds;
administration & dosage;
blood;
metabolism;
urine;
Rats;
Rats, Sprague-Dawley;
Spectrometry, Mass, Electrospray Ionization
- From:
Acta Pharmaceutica Sinica
2010;45(5):627-631
- CountryChina
- Language:Chinese
-
Abstract:
This study is to elucidate the metabolic pathway of 1,2-[bis (1,2-benzisoselenazolone-3 (2H)-ketone)]-ethane (BBSKE) in rats. Rats were administrated with a single dose of BBSKE 200 mg x kg(-1). The metabolites in rat urine, feces, bile and plasma were identified by LC-MSn analysis. The characterization of fragment ions from LC-MSn chromatography and mass spectrometry was applied to the investigation of structures of metabolites. Three phase I metabolites were detected in rat urine and feces. Two of them were also found in plasma and one existed in bile. These products were derived from oxidized, methylated and S-methylated BBSKE, separately. One phase II glucuronide of BBSKE was also found in bile. Therefore, it is possible that BBSKE was metabolized by oxidization, methylation and glucuronidation.
